Comment by layer8

A rebranding to a non-prescription drug will depend on how the prevalence × severity of side effects [0] turns out longer-term. I hope that you are right, but it seems too early to tell.

[0] https://www.sciencedirect.com/science/article/pii/S266736812...

https://www.gov.uk/drug-safety-update/glp-1-receptor-agonist...